Chapter 1 Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
Chapter 2 Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
Chapter 3 Market Analysis
3.1 Industry Value Chain Analysis
3.2Porter's Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 PESTLE Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.5 Y-O-Y Analyses
Chapter 4 Market Dynamics
4.1 DROC
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
Chapter 5 Market Segmentation Analysis
Chapter 6 Market Segmentation by Product
6.1 Reagents
6.2 Kits
6.3 Enzymes
6.4 Instruments
Chapter 7 Market Segmentation by Technology
7.1 DNA Methylation
7.2 Histone Modifications
7.3 RNA Interference
Chapter 8 Market Segmentation by End-User
8.1 Pharmaceutical
8.2 Biotechnology
8.3 Contract Research Organisation.
Chapter 9 Market Segmentation by Geography
9.1 North America
9.1.1 Introduction
9.1.2 United States
9.1.3 Canada
9.1.4 Mexico
9.1.5 Others
9.2 Europe
9.2.1 Introduction
9.2.2 Spain
9.2.3 UK
9.2.4 France
9.2.5 Russia
9.2.6 Italy
9.2.7 Others
9.3 Asia Pacific
9.3.1 Introduction
9.3.2 China
9.3.3 India
9.3.4 Japan
9.3.5 Australia & New Zealand
9.3.6 Others
9.4 The Middle East and Africa
9.4.1 Introduction
9.4.2 South Africa
9.4.3 Middle East Countries
9.4.4 Others
9.5 South America
9.5.1 Introduction
9.5.2 Argentina
9.5.3 Brazil
9.5.5 Others
Chapter 10 Competitive Landscape
10.1 Mergers & Acquisitions, Joint Ventures, Collaborations, and Agreements
10.2 Market Share Analysis
10.3 Strategies Adopted By Top Companies
Chapter 11 Company Profiles
11.1 Covaris Inc.
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Benchmarking
11.1.4. Strategic Initiative
11.2 4SC
11.3 Epiontis
11.4 Celgene
11.5 Epizyme
11.6 Cellcentric
11.7 Merck Millipore
11.8 Karus Therapeutics
11.9 Gilead Sciences Inc.
11.10 Illumina Inc.
11.11 Ribimed Biotechnologies
11.12 Eisai Co. Ltd.
11.13 Novartis AG
11.14 Qiagen
11.15 Diagenode
Chapter 12 Market Estimates and Forecasting
12.1 Market Estimates and Forecasting 2018-2024(USD Million)
12.1.1 Market Estimation and Forecasting by Product 2018-2024 (USD Million)
12.1.2 Market Estimation and Forecasting by Technology 2018-2024 (USD Million)
12.1.3 Market Estimates and Forecasting by End-User 2018-2024 (USD Million)
12.1.4 Market Estimates and Forecasting by Geography 2018-2024 (USD Million)
Chapter 13 Market Insights
13.1 Insights of Industry Experts
13.2 Analyst Opinion (Market Understanding)
13.3 Investment Opportunities
Chapter 14 Appendix
14.1 List of Tables
14.2 List of Figures
